Piper Sandler Reports Strong Q4 Earnings Amid Market Decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 03 2026
0mins
Should l Buy PIPR?
Source: Fool
Piper Sandler Companies (NYSE: PIPR) saw its stock price drop by 5.89% as it hit a 20-day low, reflecting broader market weakness with the Nasdaq-100 down 2.00% and the S&P 500 down 1.57%.
The company released its Q4 2025 earnings, reporting a Non-GAAP EPS of $6.88, which exceeded expectations by $2.12. Additionally, adjusted revenues reached $635 million, marking a 27.3% year-over-year increase. Despite the overall market decline, Piper Sandler's strong performance in the investment banking sector, particularly in advisory revenues, positions it well for future growth, especially following Goldman Sachs' upgrade to Buy.
This strong earnings report, coupled with a positive outlook for 2026, suggests that Piper Sandler is navigating market challenges effectively. The company's commitment to shareholder returns, including a special cash dividend, further enhances its appeal to investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PIPR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PIPR
Wall Street analysts forecast PIPR stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 327.200
Low
386.00
Averages
386.00
High
386.00
Current: 327.200
Low
386.00
Averages
386.00
High
386.00
About PIPR
Piper Sandler Companies is an investment bank and institutional securities firm, serving the needs of corporations, private equity groups, public entities, non-profit entities and institutional investors in the United States and internationally. The Company operates in one segment, providing investment banking services, institutional sales and trading services for various equity and fixed income products, and research services. It provides a broad set of products and services, including financial advisory services; equity and debt capital markets products; public finance services; institutional brokerage services; fundamental equity and macro research services; fixed income services; and alternative asset management strategies. The Company operates alternative asset management funds in merchant banking and healthcare in order to invest firm capital and to manage capital from outside investors. It offers both equity and fixed income advisory and trade execution services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Chewy, Inc. Stock Analysis and Outlook
- Stock Performance: On February 13, Chewy, Inc. (NYSE:CHWY) stock fell to $24.06, slightly above its 52-week low of $24.02, indicating market concerns about its short-term performance, despite analysts' optimism for its future.
- Analyst Ratings: Despite the stock's decline, 72% of analysts remain bullish on Chewy, with Piper Sandler reaffirming an Overweight rating and a price target of $48, reflecting confidence in the company's long-term growth potential.
- Earnings Expectations: Piper Sandler highlights that Chewy's earnings for 2025 are nearing consensus estimates, but with only a 3% EBITDA beat year-to-date compared to an average of 22% in 2024, indicating a slowdown in earnings growth.
- Sales Growth Forecast: While the market expects Chewy's sales growth to be around 8%, Piper Sandler projects a growth rate of 7-8%, showcasing the challenges the company faces in the competitive pet food market.
See More
SL Green Appears Undervalued, Yet Mamdani's Tax Proposal Poses a Risk
- Stock Valuation: Shares of SL Green Realty, a major player in Manhattan's office market, are perceived as undervalued.
- Dividend Yield Risk: The company's 7.8% dividend yield comes with associated risks that investors need to consider.
See More
Wolfspeed Appoints New VP of Sales for EMEA Region
- Leadership Change: Wolfspeed announced the appointment of Stefan Steyerl as Vice President of Sales for the Europe, Middle East, and Africa region, effective March 1, aiming to drive growth in the region; Steyerl previously held senior leadership roles at Analog Devices, overseeing global revenues exceeding $750 million.
- Customer Base Expansion: Steyerl's appointment is expected to broaden Wolfspeed's customer base across key markets such as AI data centers, renewable energy, industrial power systems, and electric vehicles, indicating a strategic move to diversify market demand.
- Market Performance: Wolfspeed has a market capitalization of $862.10 million, with a staggering 184.52% stock price increase over the past 12 months, currently trading at $19.05, which is approximately 38.8% above its 52-week low, demonstrating strong market performance and investor confidence.
- Analyst Rating: In early February, Piper Sandler reiterated an Overweight rating on Wolfspeed, raising its price target from $6 to $20, reflecting optimistic expectations regarding the company's future growth potential.
See More
Reasons Tech Stocks Might Underperform as Market Rally Expands Beyond AI
- AI Fears Impacting Stocks: Concerns about artificial intelligence are affecting tech-related stocks, indicating a shift in market sentiment.
- Sector's Future Uncertain: While the tech sector may still have potential, it appears it will need to share attention with other emerging trends.
See More
Analyst Reiterates Bullish Stance on Edgewise Stock
- Analyst Recommendation: Yasmeen Rahimi from Piper Sandler reiterated her overweight rating on Edgewise Therapeutics, setting a $51 price target, which contributed to a 4% stock increase, significantly outperforming the S&P 500's 0.5% rise.
- Clinical Trial Progress: Edgewise's cardiovascular drug candidate EDG-7500 is currently in Phase 2 clinical trials, with results expected in Q2 of this year, and if approved, it will provide an innovative solution for hypertrophic cardiomyopathy, enhancing market competitiveness.
- Market Potential: Rahimi considers Edgewise one of Piper Sandler's best stock picks for this year, based on its leading cardiovascular drug development and the potential of other pipeline projects, indicating strong prospects in the biotech sector.
- Muscle Development Treatment: In addition to cardiovascular drugs, Edgewise is advancing Sevasemten, a treatment for muscular dystrophy, showcasing the company's research capabilities and market opportunities across multiple therapeutic areas.
See More
Analyst Reiterates Bullish Stance on Edgewise
- Analyst Recommendation: Yasmeen Rahimi from Piper Sandler reiterated her buy rating on Edgewise Therapeutics (NASDAQ: EWTX) with a price target of $51 per share, demonstrating strong confidence in the company and likely attracting more investor interest.
- Stock Price Surge: Following the analyst's positive assessment, Edgewise's stock rose by 4% on Monday, significantly outperforming the S&P 500's 0.5% increase, reflecting market recognition of the company's potential.
- Clinical Trial Progress: Edgewise's cardiovascular drug candidate, EDG-7500, is currently in Phase 2 clinical trials, with results expected this quarter; approval could provide the company with a significant competitive edge in the market.
- Pipeline Potential: In addition to EDG-7500, Rahimi highlighted that Edgewise has solid potential in other drug developments, particularly with Sevasemten for muscular dystrophy, further enhancing the company's market outlook.
See More
Chewy, Inc. Stock Analysis and Outlook
- Stock Performance: On February 13, Chewy, Inc. (NYSE:CHWY) stock fell to $24.06, slightly above its 52-week low of $24.02, indicating market concerns about its short-term performance, despite analysts' optimism for its future.
- Analyst Ratings: Despite the stock's decline, 72% of analysts remain bullish on Chewy, with Piper Sandler reaffirming an Overweight rating and a price target of $48, reflecting confidence in the company's long-term growth potential.
- Earnings Expectations: Piper Sandler highlights that Chewy's earnings for 2025 are nearing consensus estimates, but with only a 3% EBITDA beat year-to-date compared to an average of 22% in 2024, indicating a slowdown in earnings growth.
- Sales Growth Forecast: While the market expects Chewy's sales growth to be around 8%, Piper Sandler projects a growth rate of 7-8%, showcasing the challenges the company faces in the competitive pet food market.
See More
SL Green Appears Undervalued, Yet Mamdani's Tax Proposal Poses a Risk
- Stock Valuation: Shares of SL Green Realty, a major player in Manhattan's office market, are perceived as undervalued.
- Dividend Yield Risk: The company's 7.8% dividend yield comes with associated risks that investors need to consider.
See More
Wolfspeed Appoints New VP of Sales for EMEA Region
- Leadership Change: Wolfspeed announced the appointment of Stefan Steyerl as Vice President of Sales for the Europe, Middle East, and Africa region, effective March 1, aiming to drive growth in the region; Steyerl previously held senior leadership roles at Analog Devices, overseeing global revenues exceeding $750 million.
- Customer Base Expansion: Steyerl's appointment is expected to broaden Wolfspeed's customer base across key markets such as AI data centers, renewable energy, industrial power systems, and electric vehicles, indicating a strategic move to diversify market demand.
- Market Performance: Wolfspeed has a market capitalization of $862.10 million, with a staggering 184.52% stock price increase over the past 12 months, currently trading at $19.05, which is approximately 38.8% above its 52-week low, demonstrating strong market performance and investor confidence.
- Analyst Rating: In early February, Piper Sandler reiterated an Overweight rating on Wolfspeed, raising its price target from $6 to $20, reflecting optimistic expectations regarding the company's future growth potential.
See More
Reasons Tech Stocks Might Underperform as Market Rally Expands Beyond AI
- AI Fears Impacting Stocks: Concerns about artificial intelligence are affecting tech-related stocks, indicating a shift in market sentiment.
- Sector's Future Uncertain: While the tech sector may still have potential, it appears it will need to share attention with other emerging trends.
See More
Analyst Reiterates Bullish Stance on Edgewise Stock
- Analyst Recommendation: Yasmeen Rahimi from Piper Sandler reiterated her overweight rating on Edgewise Therapeutics, setting a $51 price target, which contributed to a 4% stock increase, significantly outperforming the S&P 500's 0.5% rise.
- Clinical Trial Progress: Edgewise's cardiovascular drug candidate EDG-7500 is currently in Phase 2 clinical trials, with results expected in Q2 of this year, and if approved, it will provide an innovative solution for hypertrophic cardiomyopathy, enhancing market competitiveness.
- Market Potential: Rahimi considers Edgewise one of Piper Sandler's best stock picks for this year, based on its leading cardiovascular drug development and the potential of other pipeline projects, indicating strong prospects in the biotech sector.
- Muscle Development Treatment: In addition to cardiovascular drugs, Edgewise is advancing Sevasemten, a treatment for muscular dystrophy, showcasing the company's research capabilities and market opportunities across multiple therapeutic areas.
See More
Analyst Reiterates Bullish Stance on Edgewise
- Analyst Recommendation: Yasmeen Rahimi from Piper Sandler reiterated her buy rating on Edgewise Therapeutics (NASDAQ: EWTX) with a price target of $51 per share, demonstrating strong confidence in the company and likely attracting more investor interest.
- Stock Price Surge: Following the analyst's positive assessment, Edgewise's stock rose by 4% on Monday, significantly outperforming the S&P 500's 0.5% increase, reflecting market recognition of the company's potential.
- Clinical Trial Progress: Edgewise's cardiovascular drug candidate, EDG-7500, is currently in Phase 2 clinical trials, with results expected this quarter; approval could provide the company with a significant competitive edge in the market.
- Pipeline Potential: In addition to EDG-7500, Rahimi highlighted that Edgewise has solid potential in other drug developments, particularly with Sevasemten for muscular dystrophy, further enhancing the company's market outlook.
See More
